Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesevatinib in recurrent glioblastoma
NCT02844439Phase 2Completed
- Sponsor
- Kadmon
- Start
- Jun 2016
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tesevatinib in glioblastoma (GBM), sponsored by Kadmon. Started Jun 2016; status: completed.
02
Drugs
tesevatinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02844439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02844439.